Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Vanda Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 203

Market Cap: $311.8M

Website

Introduction: Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Clinical Trials

Open-Label Evaluation of Relapse Prevention in Patients With Schizophrenia

Phase 3

Not yet recruiting

Conditions: Schizophrenia

Interventions: Drug: iloperidone

First Posted Date: 2025-05-08

Last Posted Date: 2025-05-08

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT06961968

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

Phase 3

Recruiting

Conditions: Insomnia Disorder

Interventions: Drug: Tasimelteon Oral Suspension
Drug: Placebo

First Posted Date: 2025-05-01

Last Posted Date: 2025-05-01

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 420

Registration Number: NCT06953869

Locations: 🇺🇸
Vanda Investigational Site, San Antonio, Texas, United States

Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis

Phase 3

Recruiting

Conditions: Idiopathic Gastroparesis
Diabetic Gastroparesis
Gastroparesis

Interventions: Drug: Tradipitant

First Posted Date: 2025-02-20

Last Posted Date: 2025-02-20

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT06836557

Locations: 🇩🇪
Vanda Investigational Site, Leipzig, Germany

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

Phase 3

Recruiting

Conditions: Major Depressive Disorder (MDD)

Interventions: Drug: Milsaperidone
Drug: Placebo

First Posted Date: 2025-02-17

Last Posted Date: 2025-05-25

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 500

Registration Number: NCT06830044

Locations: 🇺🇸
Vanda Investigational Site, Richardson, Texas, United States

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

Phase 2

Recruiting

Conditions: Obesity

Interventions: Drug: Placebo
Drug: Tradipitant

First Posted Date: 2025-02-03

Last Posted Date: 2025-07-04

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT06804603

Locations: 🇺🇸
Vanda Investigational Site, New York, New York, United States

Food Effect Study of VHX-896 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: VHX-896

First Posted Date: 2025-01-31

Last Posted Date: 2025-01-31

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT06803290

Locations: 🇺🇸
Vanda Investigational Site, Springfield, Missouri, United States

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant

Phase 3

Recruiting

Conditions: Sleep Wake Disorders
Sleep Disorders, Circadian Rhythm
Chronobiology Disorders
Gene Mutations and Other Alterations Nec

Interventions: Drug: Placebo
Drug: Tasimelteon

First Posted Date: 2024-11-22

Last Posted Date: 2024-11-22

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT06701396

Locations: 🇹🇷
Vanda Investigational Site, Çankaya, Ankara, Turkey

Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions

Phase 1

Not yet recruiting

Conditions: Schizophrenia
Bipolar I Disorder

Interventions: Drug: VHX-896 and iloperidone
Drug: Iloperidone and VHX-896

First Posted Date: 2024-07-10

Last Posted Date: 2024-07-10

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT06494397

Locations: 🇺🇸
Vanda Investigational Site, Marlton, New Jersey, United States

Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Tasimelteon
Drug: Active Control
Drug: Active Control Placebo
Drug: Tasimelteon Placebo

First Posted Date: 2024-03-21

Last Posted Date: 2024-03-21

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT06323655

Locations: 🇨🇦
Vanda Investigational Site, Laval, Quebec, Canada

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Phase 2

Recruiting

Conditions: Dry Eye

Interventions: Drug: Placebo
Drug: VSJ-110

First Posted Date: 2024-03-06

Last Posted Date: 2024-03-06

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT06296966

Locations: 🇺🇸
Vanda Investigational Site, Andover, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy